Latest news with #Essity
The Sun
3 days ago
- Health
- The Sun
Poor quality incontinence care is contributing to NHS bed blocking crisis, experts say
UK medical experts claim poor quality incontinence care is contributing to the NHS bed blocking crisis. A study of 500 medical professionals who care for patients with incontinence found 29 per cent believe beds are currently blocked by people in hospital who would be able to go home sooner, were the levels of medical counsel and quality of provisions better. 2 And 24 per cent believe the mismanagement of incontinence, specifically, can lead to a delay in patient discharge. In addition, 61 per cent of experts polled by hygiene and health company Essity, said there are patients who are being admitted to hospital or care facilities with incontinence related conditions, due to previous mismanagement of their situation. The current high bed occupancy rates, which sit consistently above 95 per cent, could be reduced significantly were the government to fast track a new policy announced by House of Lords member Lord Philip Hunt, in May 2024. But the implementation of the policy, stipulating that the total cost of care including patient experience and outcomes must be considered ahead of simply the cost per product, has been delayed by several months. Mr. Mark Stott, consultant urologist, believes a number of beds could be released earlier, if patients received a tailored programme of care, along with better quality incontinence products. He said: 'Improved continence care and the best use of products will reduce unplanned admissions and would facilitate discharge in many older patients. 'Incontinence is a key factor affecting the package of care, early discharge or residential placement in a number of patients. 'We know a good continence care plan can contribute to patients getting home more quickly; it is that package of care which allows them to become independent again, and which speeds up their recovery. 'Early supported discharge, with a tailored plan - which takes into account the patient's individual needs, the reason for their incontinence, their physical and mental ability – can prevent help to reduce length of stay, relapses and readmittances.' Exactly six in 10 questioned in the study said urinary tract infections could be dealt with more effectively, while 54 per cent said there should be better education on incontinence overall. Social care, pressure ulcers and better care provision for mental and physical health (52 per cent respectively) were all cited as things which could be handled better for those patients with incontinence, to prevent admission to hospital in the first place, or avoid a delay in discharge. Medical experts also feel there should be better provision of incontinence products to aid care (47 per cent), and long-term patient healthcare (45 per cent). However, only a third of those polled via are yet aware of the proposed policy change in the way the NHS procures its medical supplies. Although 54 per cent are convinced that when this does come into play, it will enable patients to live a more dignified life, and 53 per cent think it will improve the quality of care on offer from the NHS. Just under four in 10 (39 per cent) believe they would see a distinct improvement in the mental and physical health of patients. While 35 per cent said the introduction of 'patient first' procurement would result in the earlier discharge of incontinence patients from a hospital or care home setting. And 32 per cent firmly think it will prevent them from being admitted in the first place. Richard Maddison, spokesperson for Essity said: 'It's clear when you speak to healthcare professionals that the way in which the NHS procures medical products has to change. 'Choosing the cheapest product believing it will save money is a huge false economy that not only ends up costing the health service more in the long run, but it completely disregards the negative knock-on effects such as unnecessary admissions, bed blocking, patient dignity, and ultimately the outcome for the patient. 'The current approach to procurement has a hugely detrimental impact on patients, their families, and healthcare professionals. The answer is not more money for the NHS, the answer is a smarter way to spend the money it has now.' 2
North Wales Live
3 days ago
- Health
- North Wales Live
NHS bed blocking crisis as poor continence care 'contributing to issue'
UK healthcare professionals are voicing concerns that inadequate incontinence care may be worsening the NHS bed-blocking issue. A survey involving 500 medical workers who attend to patients with incontinence found a prevalent opinion that better medical recommendations and superior care supplies could hasten the discharge of individuals occupying hospital beds unnecessarily. The research, carried out by hygiene and health company Essity, indicated that suboptimal handling of incontinence has led to admissions or prolonged stays in hospitals and care homes. Additionally, one in four respondents believed that the poor management of these conditions contributes to patient discharge delays. An Essity representative has indicated that if the government accelerates the implementation of a policy proposed by Lord Philip Hunt in May 2024 which favours patient experience and outcomes over cost, it greatly alleviates the high rates of bed occupancy. Despite its announcement, the policy's roll-out has faced several months of postponement. Consultant urologist Mr. Mark Stott is an advocate for customised care plans and higher-grade incontinence products, suggesting such measures could expedite bed availability. He said: "Incontinence is a key factor affecting the package of care, early discharge or residential placement in a number of patients. "We know a good continence care plan can contribute to patients getting home more quickly; it is that package of care which allows them to become independent again, and which speeds up their recovery." He added: "Early supported discharge, with a tailored plan - which takes into account the patient's individual needs, the reason for their incontinence, their physical and mental ability – can prevent help to reduce length of stay, relapses and readmittances." The majority of professionals believe the new policy, once implemented, will enhance patient dignity, help improve patients' mental and physical health and prevent many from being admitted in the first place. The survey also found that six out of 10 professionals believe urinary tract infections could be managed more effectively, while 54 per cent called for better education on incontinence overall. Social care, pressure ulcers and improved care for mental and physical health were all pinpointed as areas that could be better managed for patients suffering from incontinence. Richard Maddison, spokesperson for Essity, said: "It's clear when you speak to healthcare professionals that the way in which the NHS procures medical products has to change. "Choosing the cheapest product believing it will save money is a huge false economy that not only ends up costing the health service more in the long run, but it completely disregards the negative knock-on effects such as unnecessary admissions, bed blocking, patient dignity, and ultimately the outcome for the patient. "The current approach to procurement has a hugely detrimental impact on patients, their families, and healthcare professionals. The answer is not more money for the NHS, the answer is a smarter way to spend the money it has now."
Bloomberg
4 days ago
- Business
- Bloomberg
Vertical Farms Bet on Berries, Microgreens After Bankruptcies
By Welcome to The Brink. I'm Georgia Hall in New York, where I looked at vertical farming companies bouncing back after a string of financial debacles. We also have news on Southern European banks, Essity and New World. Follow this link to subscribe. Send us feedback and tips at debtnews@ After a spate of bankruptcies, the high-tech vertical farming industry is turning to trendy microgreens and berries to make their operations profitable.
Bloomberg
5 days ago
- Business
- Bloomberg
Essity's Attempt to Dismiss Bondholder Lawsuit Rejected by Court
A London judge rejected Essity AB 's request to dismiss a lawsuit by a group of bondholders including Oaktree Capital Management and Sona Asset Management, who claim the Swedish personal-care company breached debt terms and owe early repayment. 'There is a serious issue to be tried,' wrote Judge Timothy Fancourt of the London High Court in a judgment handed down on Monday. A lawyer for Essity had argued at a hearing in May that there wasn't, and that the plaintiffs who brought the suit aren't the 'proper parties' to bring such claims as they didn't directly hold the notes.
Yahoo
28-05-2025
- Business
- Yahoo
Compression Therapy Market worth US$5.9 billion by 2030 with 5.5% CAGR
DELRAY BEACH, Fla., May 28, 2025 /PRNewswire/ -- The global Compression Therapy Market, valued at US$4.3 billion in 2024 stood at US$4.5 billion in 2025 and is projected to advance at a resilient CAGR of 5.5% from 2024 to 2030, culminating in a forecasted valuation of US$5.9 billion by the end of the period. The key factor driving the compression therapy market is the increasing prevalence of venous disorders and lymphedema, particularly among the elderly and post-surgical patients. Additionally, the rising rates of obesity and advancements in smart compression devices are further boosting demand in this market. Additionally, the growing prevalence of obesity and the rising number of orthopaedic procedures have increased the demand for compression therapy devices. Obesity leads to circulation problems, and post-surgical patients often need compression therapy to prevent complications and support recovery. Download PDF Brochure: Browse in-depth TOC on "Compression Therapy Market" 400 - Tables100 - Figures400 - Pages By Based on Application, the varicose veins segment is the leading segment of the compression therapy market due to its direct link to the rising prevalence of this condition, especially among aging populations and individuals whose jobs require prolonged standing. Compression therapy effectively alleviates symptoms of varicose veins, such as pain and swelling, by enhancing venous return and reducing pressure in the affected vessels. The growing preference for non-invasive treatments, along with an increasing demand for home-based care options, positions compression therapy as an important therapeutic choice. Additionally, advancements in the design of compression garments, which offer improved comfort and effectiveness, further strengthen its role in this field. By Based on Product, Compression bandages dominate the compression therapy market, particularly due to their essential role in managing venous leg ulcers (VLUs) and early-stage lymphedema during decongestive therapy. Multi-layer systems allow clinicians to tailor pressure levels based on limb circumference changes, making them more suitable than fixed-pressure garments in active wound management. Clinical protocols, such as those recommended by NICE in the UK, prioritize bandage systems for ulcer healing. Companies like Essity (with its JOBST Comprilan and Leukotape product lines) and 3M (offering the Coban 2 Layer Compression System) are key players driving adoption through specialized solutions designed for effective pressure distribution, moisture control, and ease of application. The compression therapy market is experiencing significant innovation, especially with the integration of digital health technologies. These advancements include pressure-sensing systems that provide real-time feedback to both clinicians and patients. Velcro-based adjustable wraps are becoming more popular, enabling users to manage their therapy easily outside of clinical settings, which supports the trend toward decentralized care. Custom-fit solutions, created using 3D scanning or sizing tools, are also gaining traction as they offer better therapeutic outcomes through precise compression. To address challenges related to long-term wear, companies are developing lightweight, breathable fabrics that minimize skin irritation. Additionally, sustainability is becoming a key differentiator, with some companies exploring biodegradable or reusable compression materials to help reduce medical waste. By geography, the US holds a significant share of the compression therapy market for several important reasons. First, there is a high prevalence of chronic venous diseases, such as varicose veins and lymphedema, which creates a consistent demand for compression therapies. Additionally, the aging population contributes significantly to this demand, as older adults are more susceptible to conditions that require these treatments. Moreover, the growing number of orthopedic surgeries and the subsequent need for post-surgical care also drive the market, as compression therapy is commonly used to manage swelling and promote recovery. The US also benefits from a robust healthcare infrastructure, widespread access to specialized care, and favorable reimbursement policies, all of which encourage the adoption of compression therapy. Finally, the presence of major companies, such as 3M and Essity, which are leaders in product innovation and availability, ensures the market's ongoing growth and accessibility. Request Sample Pages : As of 2024, the key players in the compression therapy market are BSN Medical (Germany), medi GmbH & Co. KG (Germany), 3M Company (US), Sanyleg S.r.l. (Italy), SIGVARIS AG (Switzerland), Juzo GmbH (Germany), Lohmann & Rauscher GmbH & Co. KG (Germany), VENOSAN (Switzerland), DJO Global, Inc. (US), Essity AB (Sweden), Smith & Nephew Plc (UK), Medline Industries, LP (US), Gottfried Medical, Inc. (US), Stryker Corporation (US), Össur hf. (Iceland), Mego Afek AC Ltd. (Israel), ConvaTec Group Plc (UK), Cardinal Health, Inc. (US), Spectrum Healthcare (US), THUASNE (France), and Medtronic Plc (Ireland). BSN Medical (Germany): BSN Medical an Essity company, has strengthened its leadership in global compression therapy through innovation, strategic partnerships, and international expansion. The company continues to enhance its market-leading JOBST range by utilizing advanced technologies such as SoftFit for improved comfort and compliance, sensitive top bands for moisture control, and 3D-knitted seamless garments that provide an anatomical fit, like the JOBST Elvarex Plus. BSN has reinforced its market position through acquisitions, such as Wright Therapy Products, and collaborations with companies like Terumo Medical Corporation in Japan and Ortopédicos Futuro in Colombia, which have expanded its distribution reach. Additionally, the integration of BSN Medical India into Essity India and the establishment of manufacturing centers in Goa demonstrate the company's commitment to emerging markets and sustainability. These sites operate globally in alignment with Essity's sustainability framework. Other products, such as JOBST Compri2 and the stylish JOBST UltraSheer, reflect BSN's commitment to both clinical performance and consumer preferences, reinforcing its position as a leader in compression therapy. Medi GmbH & Co. KG (Germany) Medi GmbH & Co. KG is a leading manufacturer of medical compression therapy products. The company is well-known for its wide range of medical compression stockings, orthopedic supports, and wound care solutions. Medi serves both clinical and consumer markets under its key brands, Mediven and Circaid, which focus on venous and lymphatic disorders. Medi has a strong presence across Europe, North America, and Asia, with production facilities in Germany and subsidiaries in over 20 countries. The company prioritizes evidence-based product development and uses advanced materials that combine medical effectiveness with patient comfort. Additionally, Medi invests in patient education and digital solutions to promote long-term adherence to therapy. 3M (US) 3M is a leading player in the compression therapy market, known for its clinically validated products that promote wound healing and support vascular health. The company's compression therapy offerings include cohesive bandages, compression wraps, and multi-layer systems, which are widely used in both hospital and home care settings. 3M has a strong global presence across North America, Europe, Asia Pacific, and Latin America. Its solutions effectively address conditions such as venous leg ulcers, lymphedema, and chronic edema. The product line features well-known brands like Coban and ActiWrap, which offer consistent pressure delivery and ease of application. These products are primarily marketed through 3M's Medical Solutions division. 3M emphasizes product innovation and strategic collaborations to maintain its competitive advantage. For example, the company has focused on integrating its products with wound care portfolios and pressure mapping technologies to improve clinical outcomes and enhance the user experience. For more information, Inquire Now! Related Reports: Orthopedic Braces & Supports Market Cold Pain Therapy Market OTC Braces & Supports Market Orthopedic Devices Market Orthopedic Implants Market Get access to the latest updates on Compression Therapy Companies and Compression Therapy Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets Sign in to access your portfolio
